Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion for clot-dissolving agent TNKase (tenecteplase) – the first ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...